The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SLRX | -96% | -99.98% | -80.98% | -100% |
| S&P | +12.66% | +85.37% | +13.13% | +239% |
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.
No news articles found for Salarius Pharmaceuticals.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.00M | -0.1% |
| Market Cap | $3.44M | 65.9% |
| Market Cap / Employee | $1.72M | 0.0% |
| Employees | 2 | 0.0% |
| Net Income | -$0.87M | 10.1% |
| EBITDA | -$0.89M | 11.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.81M | 46.5% |
| Accounts Receivable | $0.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | -100.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -100.54% | -19.1% |
| Return On Invested Capital | -195.32% | -60.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.65M | -21.4% |
| Operating Free Cash Flow | -$1.65M | -21.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.75 | 25.37 | -2.30 | -0.63 | -188.40% |
| Price to Tangible Book Value | 13.60 | 10.78 | 452.22 | -0.63 | -110.76% |
| Enterprise Value to EBITDA | -0.30 | 0.25 | -1.15 | 3.40 | 208.41% |
| Return on Equity | -164.0% | -300.2% | -660.4% | -139.6% | 25.87% |
| Total Debt | $0.22M | $0.11M | $0.00M | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
